# Run A Review-Packet Builder Implementation Gate

Stewarded by [frg.earth](https://frg.earth/).

## Boundary

Research-use only. This task is not medical advice, diagnostic guidance,
treatment guidance, trial guidance, eligibility guidance, expanded-access
guidance, clinical prioritization, generated biomedical claims, publication
authorization, or a cure claim.

This task should create an aggregate implementation gate only. It should not
build a review-packet builder, generator, dashboard, explorer, ranking tool,
trial finder, patient matcher, recommendation system, generated packet output,
or generated-claim pipeline.

## Why This Matters

[Review-Packet Builder Manifest Schema v0](../../../schemas/review-packet-builder-manifest-schema-v0.md)
and [Review-Packet Builder Dry-Run Plan v0](../../reviews/review-packet-builder-dry-run-plan-v0.md)
now define the public manifest shape and no-code dry-run behavior for future
review-packet-builder inputs.

The next finite endpoint is an aggregate gate that decides whether builder
implementation remains blocked or whether a smallest safe code slice can be
selected. The gate must happen before code.

## Status

Completed by [Review-Packet Builder Implementation Gate v0](../../reviews/review-packet-builder-implementation-gate-v0.md).
The next public-safe endpoint is
`multiple-myeloma-review-packet-builder-route-table-script-task-v0`.

## Public Source Anchors

- `pubmed`
- `clinicaltrials_gov_api_v2`
- `nci_pdq_myeloma_hp`
- `hgnc_gene_names`
- `nci_cancer_drug_dictionary`

## Linked Public Artifacts

- `multiple-myeloma-review-packet-builder-dry-run-plan-v0`
- `review-packet-builder-manifest-schema-v0`
- `multiple-myeloma-review-packet-builder-manifest-spec-v0`
- `multiple-myeloma-tooling-readiness-gate-v0`
- `multiple-myeloma-schema-tooling-phase-inventory-v0`
- `multiple-myeloma-open-research-map-v0-1`
- `multiple-myeloma-roadmap-public-task-queue-v0`
- `multiple-myeloma-multidisciplinary-review-packet-template-v0`

## Deliverables

- Add a public aggregate implementation gate for review-packet-builder code
  readiness.
- Include a decision table for schema validation, dry-run behavior,
  no-generated-claims policy, refusal behavior, output boundaries, and missing
  inputs.
- Decide whether builder implementation remains blocked or whether a smallest
  safe code slice is selected.
- Keep the gate no-code.
- Update catalog, roadmap, readiness gate, task queue, and open research map
  links if the gate becomes a public artifact.

## Acceptance Checks

- `make validate` passes.
- The gate references Review-Packet Builder Manifest Schema v0 and Review-Packet
  Builder Dry-Run Plan v0.
- The gate states whether builder implementation remains blocked or a smallest
  safe code slice is selected.
- The gate does not add builder code, generated packet output, generated
  biomedical claims, ranking behavior, trial matching, recommendation behavior,
  or patient-specific interpretation.
- If a future code slice is selected, it is limited to copied public
  identifiers, public paths, boundary text, validation status, and explicit
  missing-input reports.

## Do Not Infer

- Do not infer that an implementation gate authorizes clinical use.
- Do not infer expert review, evidence strength, clinical importance, patient
  relevance, actionability, or publication authorization from implementation
  readiness.
- Do not use readiness-gate outputs for treatment selection, trial selection,
  expanded-access decisions, or cure claims.
- Do not rank questions, trials, therapies, products, targets, sources,
  mechanisms, artifacts, tasks, or evidence by clinical priority.
